Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Published online December 5, 2003.
Copyright & Usage
THE JOURNAL OF NUCLEAR MEDICINE
Author Information
- Robert M. Sharkey, PhD1,
- Arnold Brenner, DO1,
- Jack Burton, MD1,
- George Hajjar, MD1,
- Stephen P. Toder, MD1,
- Abass Alavi, MD2,
- Alexander Matthies, MD2,
- Donald E. Tsai, MD2,
- Stephen J. Schuster, MD2,
- Edward A. Stadtmauer, MD2,
- Myron S. Czuczman, MD3,
- Dominick Lamonica, MD3,
- Françoise Kraeber-Bodere, MD4,
- Beatrice Mahe, MD4,
- Jean-François Chatal, MD4,
- André Rogatko, PhD5,
- George Mardirrosian, PhD6 and
- David M. Goldenberg, ScD, MD1
- 1Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, New Jersey
- 2Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania
- 3Roswell Park Cancer Center, Buffalo, New York
- 4University Hospital, René Gauducheau Cancer Center, Nantes, France
- 5Fox Chase Cancer Center, Philadelphia, Pennsylvania
- 6University of Oklahoma Health Sciences Center, Department of Radiological Sciences, Oklahoma City, Oklahoma
Statistics from Altmetric.com
Cited By...
Article usage
In this issue
Jump to section
Related Articles
Cited By...
- Anti-CD22 90Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphoma
- RADAR Commentary: Evolution and Current Status of Dosimetry in Nuclear Medicine
- High Rates of Durable Responses With Anti-CD22 Fractionated Radioimmunotherapy: Results of a Multicenter, Phase I/II Study in Non-Hodgkin's Lymphoma
- 131I-Tositumomab Radioimmunotherapy: Initial Tumor Dose-Response Results Using 3-Dimensional Dosimetry Including Radiobiologic Modeling
- Dosimetry of 90Y-Ibritumomab Tiuxetan as Consolidation of First Remission in Advanced-Stage Follicular Lymphoma: Results from the International Phase 3 First-Line Indolent Trial
- Some like it hot: lymphoma radioimmunotherapy
- A comparative analysis of conventional and pretargeted radioimmunotherapy of B-cell lymphomas by targeting CD20, CD22, and HLA-DR singly and in combinations
- A re-examination of radioimmunotherapy in the treatment of non-Hodgkin lymphoma: prospects for dual-targeted antibody/radioantibody therapy
- Therapy of Advanced B-Lymphoma Xenografts with a Combination of 90Y-anti-CD22 IgG (Epratuzumab) and Unlabeled Anti-CD20 IgG (Veltuzumab)
- Evaluation of response to fractionated radioimmunotherapy with 90Y-epratuzumab in non-Hodgkin's lymphoma by 18F-fluorodeoxyglucose positron emission tomography
- Phase I to III Trials of Anti-B Cell Therapy in Non-Hodgkin's Lymphoma
- Collimator Selection, Acquisition Speed, and Visual Assessment of 131I-Tositumomab Biodistribution in a Phantom Model
- Combination Antibody Therapy With Epratuzumab and Rituximab in Relapsed or Refractory Non-Hodgkin's Lymphoma
- Dose-Fractionated Radioimmunotherapy in Non-Hodgkin's Lymphoma Using DOTA-Conjugated, 90Y-Radiolabeled, Humanized Anti-CD22 Monoclonal Antibody, Epratuzumab
- Radioimmunotherapy of Non-Hodgkin's Lymphoma Revisited
- Dosimetry of Internal Emitters
- Antibody-Based Targeted Radiation to Pediatric Tumors
- Perspectives on Cancer Therapy with Radiolabeled Monoclonal Antibodies
- Potent and Specific Antitumor Efficacy of CMC-544, a CD22-Targeted Immunoconjugate of Calicheamicin, against Systemically Disseminated B-Cell Lymphoma
- Dosimetry and Radioimmunotherapy of Non-Hodgkin's Lymphoma
- Bias Reduction in Correlation of Radiation-Absorbed Dose with Response